Big Pharma and Biotech rankings on core metrics

30 November 2016

Independent investment research firm Morningstar has published its latest Healthcare Observer, “Strong Pipelines Support Big Biotech and Big Pharma Moats and Attractive Valuations.”

In the report, Morningstar equity analysts rank the large-cap drug companies on three core metrics by 2020: new drug sales, sales lost to generic competition, and sales from older products not facing generic competition. The report also dives into a summary of the economic moats, or sustainable competitive advantages, of Big Pharma and Biotech stocks, including intangible assets in the form of patents, diversification, and pipeline productivity.

Key highlights of the Healthcare Observer include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK